Pharmaceutical Technology21 天
Sovateltide by Pharmazz for Hypoxic-Ischemic Encephalopathy: Likelihood of Approval
Sovateltide is under clinical development by Pharmazz and currently in Phase I for Hypoxic-Ischemic Encephalopathy. According to GlobalData, Phase I drugs for Hypoxic-Ischemic Encephalopathy does not ...
emjreviews.com27 天
Machine Learning Advances Prognosis in Hypoxic-Ischemic Encephalopathy
MACHINE LEARNING models incorporating MRI-based measures improve the accuracy of predicting neurodevelopmental outcomes in neonates with hypoxic-ischemic encephalopathy (HIE), surpassing the ...
Cochrane4 年
What are the benefits and harms of acupuncture for babies with lack of oxygen at birth ...
Read the full abstract... Background: Peripartum asphyxia affects three to five per 1000 live births, with moderate or severe hypoxic ischemic encephalopathy (HIE) occurring in 0.5 to 1 per 1000 live ...
Frontiers6 年
Nitric Oxide Synthase Inhibition as a Neuroprotective Strategy Following Hypoxic–Ischemic ...
Background: Hypoxic–ischemic encephalopathy following perinatal asphyxia is a leading cause of neonatal death and disability worldwide. Treatment with therapeutic hypothermia reduced adverse outcomes ...